Dilworth IP welcomes the news that both houses of the Connecticut General Assembly recently passed S.B. 1056 before the end of the legislative session in order to “establish a working group to develop a plan to foster the microbiome sector in the state.” This bill, which will now go to the governor for consideration, aims to incentivize companies focused on microbiome research and innovation to pursue their technology within the State of Connecticut. It proposes that a working group be established to identify these companies and develop various incentives, including an annual competition for start-up microbiome-focused companies to take place in Connecticut. Research into the microbiome, which seeks to understand and positively direct the relationship between a host organism and the billions of bacteria that inhabit that organism particularly in the gut and on the skin, has produced much promise in providing therapies for diseases such as inflammatory bowel disease (IBD), childhood-onset asthma, diabetes, obesity, cardiovascular disease, and colorectal cancer to name a few. “At Dilworth IP we had early on identified the field of microbiome-based therapeutics as an up and coming research area,” Dr. Anthony Sabatelli, Partner and Chair of Dilworth IP’s Biotech and Pharmaceutical IP practice group, said, “we are very pleased that this Bill has passed the General Assembly, because it demonstrates the State’s commitment to supporting this emerging technology area as an important part of Connecticut’s biotechnology future.”

For the full text of the bill, Click Here